Bulk transcriptomic classifiers stratify pancreatic ductal adenocarcinoma (PDAC) into classical and basal-like subtypes with prognostic and therapeutic relevance, yet increasing evidence indicates tha...

Background & Aims: Prohaptoglobin (proHp), a precursor of haptoglobin (Hp), has recently emerged as a cancer-associated biomarker, but its functional role in pancreatic cancer remains unclear. We inve...

Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by late diagnosis, rapid progression, and resistance to conventional therapies. Mutations in the tumor supp...

Cell Death & Disease - LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming

For decades, we have viewed pancreatic fibrosis as a passive scar—the end-stage wreckage of chronic inflammation or a late accomplice of growing tumor…

This study introduces an innovative strategy for the tumor-selective catalytic degradation of oncogenic non-coding RNA by interfacing a ribonuclease-recruiting small molecule (RIBOTAC) with an EGFR-t...

Gemcitabine remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet the emergence of resistance constitutes a major clinical …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat due to the dismal survival rate, poor post-treatment outcome and profound resistance to a wide range of therapie...

AbstractMotivation. In recent years, the availability of multi-omics data has increased substantially. Multi-omics data integration methods mainly aim to l

Most present-day survival-models of patients with cancer do not account for tumor-host interactions. We hypothesized that host phenotypes based on sys…

Oncogene - ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer

Pancreatic cancer is among the most lethal forms of cancer, underscoring an urgent need for novel therapeutic approaches. The present study examined a protein known as SLC1A1, which facilitates the re...

Oral WT1-targeted Bifidobacterium longum vaccine promotes WT1-associated cellular immunity and enhances anti-PD-1/anti-CTLA-4 efficacy in pancreatic cancer.

In phase 1b/2 trial, the treatment of patients with metastatic KRASG12D-mutant pancreatic cancer, the intravenously delivered KRAS-G12D inhibitor HRS-4642 plus nab-paclitaxel and gemcitabine led to en...

Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive molecular and microenvironmental heterogeneity, yet how tumor lineage states interact with spatial immune organization in advanced disease re...

Pancreatic ductal adenocarcinoma (PDAC) is dependent on autophagy for growth. Chloroquine/Hydroxychloroquine (CQ/HCQ), the sole FDA-approved autophagy inhibitors, have shown limited clinical efficacy ...

Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...

Desde los fundamentos Biológicos hasta las terapias emergentes, una inmersión completa en el cáncer de páncreas.

AbstractSummary. Multi-omics data offer unprecedented insights into complex biological systems, yet their high dimensionality, sparsity, and intricate inte

Immune-enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9-driven “metabolic trap” and enh...

In KRAS-mutant pancreatic cancer, persistent downstream signaling can limit the efficacy of EGFR-targeting mAbs. However, the addition of NK cells enables nimotuzumab to effectively direct a potent a...

Cell Death & Differentiation - Inhibition of Pax6 sumoylation suppresses the tumorigenicity of pancreatic cancer cells

Check access to the full text by signing in through your organization.

Signal Transduction and Targeted Therapy - Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study

Cancer vaccines face limitations in pancreatic cancer due to insufficient tumor antigens. This ionic liquid ILvax via local tumor delivery triggers robust cDC1-dependent systemic anti-tumor immunity.....

FOLFIRINOX is standard chemotherapy for borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), but response rates remain suboptima…

Pancreatic cancer cells grow in an extremely stressful and dynamic environment. To survive and expand, these cells must precisely regulate their size and shape, making cell volume regulation a critica...

Oncogene - HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer

AbstractPurpose:. The Pancreatic Cancer Detection Consortium (PCDC) performed a blinded Early Detection Research Network–defined phase II biomarker bakeoff study of blood-based biomarker panels. The a...

Background Accumulating evidence has demonstrated that distinct tumour-promoting and tumour-restraining cancer-associated fibroblast (CAF) subtypes coexist in pancreatic ductal adenocarcinoma. Object...

This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early-stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mi....

Pancreatic cancer is the third leading cause of cancer-related death in the United States. Current chemotherapy options provide limited benefits. Emer…

Pancreatic ductal adenocarcinoma (PDAC) is resistant to current immunotherapies and lacks effective anti-tumor CD8+ T cells, which is potentially due …